Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405279 | 0.89 | DGAT1 (0.38) | ALDH1A1HSD17B10DGAT1KDM4EHPGD | |
| SCHEMBL3401320 | 0.86 | ALDH1A1 (0.42) | FBP1ALDH1A1HSD17B10KDM4EPKM | |
| SCHEMBL509029 | 0.82 | FBP1 (0.42) | FBP1ALDH1A1HSD17B10KDM4EPKM | |
| SCHEMBL1554027 | 0.77 | ALDH1A1 (0.42) | FBP1ALDH1A1HSD17B10KDM4EPKM | |
| SCHEMBL5661987 | 0.76 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL7836831 | 0.75 | MAPT (0.41) | ALDH1A1HSD17B10DGAT1KDM4EGAA | |
| SCHEMBL3405599 | 0.75 | HSP90B1 (0.38) | ALDH1A1GAA | |
| SCHEMBL403488 | 0.74 | ALDH1A1 (0.52) | FBP1ALDH1A1HSD17B10KDM4EGAA | |
| SCHEMBL29152841 | 0.73 | KDM4E (0.39) | ALDH1A1HSD17B10DGAT1KDM4EPKM | |
| SCHEMBL9638271 | 0.73 | DGAT1 (0.41) | ALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | FBP1 1677/4885ALDH1A1 243/4885HSD17B10 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.